Ignite Creation Date:
2024-05-06 @ 5:11 PM
Last Modification Date:
2024-10-26 @ 2:23 PM
Study NCT ID:
NCT05222256
Status:
UNKNOWN
Last Update Posted:
2022-02-08
First Post:
2021-12-06
Brief Title:
Comparison Between Levosimendan and Adrenaline in CABG Patients
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Levosimendan Versus Adrenaline in Patients With Low Left Ventricular Function Undergoing Elective On-Pump Coronary Artery Bypass Graft Surgery A Randomized Controlled Study
Status:
UNKNOWN
Status Verified Date:
2022-02
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to compare between levosimendan and adrenaline in patients with pre-existing impaired systolic function EF 30-40 undergoing elective on-pump CABG as regards hemodynamics and echocardiographic parameters
Detailed Description:
Patients undergoing cardiac surgery are at risk of post-cardiotomy myocardial dysfunction This condition causes delayed recovery organ failure prolonged intensive care unit and hospital stays and an increased risk of mortality These patients often require inotropic support which has been associated with an increased risk of cardiovascular complications Treatment of myocardial dysfunction includes optimization of myocardial contractility through appropriate fluid and pharmacologic management and mechanical support Extensive use of inotropes in this situation is needed but the optimal pharmacologic management of myocardial dysfunction in cardiac surgery is a matter of ongoing debate Available inotropes including adrenaline may increase myocardial oxygen consumption heart rate and risk of arrhythmia An increase in myocardial oxygen consumption by inotropes in a state of inadequate oxygen delivery may further deteriorate underlying cardiac dysfunction and even lead to increased mortality There are questions regarding the ideal inotrope to use during the post cardiopulmonary bypass CPB period in patients undergoing on-pump CABG surgery The occurrence of myocardial dysfunction after cardiac surgery is a potential indication for the use of levosimendan a calcium sensitizer with a unique mechanism of action By binding to cardiac troponin C it enhances myofilament responsiveness to calcium thereby increasing myocardial contraction without increasing myocardial oxygen consumption In addition levosimendan activates adenosine triphosphate-dependent potassium channels which are important mediators of ischemic and anesthetic cardioprotection Levosimendan might thus have a potential benefit for patients with myocardial oxygen imbalance requiring inotropic drug support The hypothesis of the present study is that levosimendan without loading dose can improve myocardial function and provide better hemodynamics as well as echocardiographic parameters compared with adrenaline in patients with low ejection fraction undergoing op-pump CABG
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None